
CLARITIN Drug Profile, 2019 - Patents, Clinical Trials, Drug Prices, Annual Sales Revenues and Raw API Sources - ResearchAndMarkets.com
The "CLARITIN Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.
CLARITIN Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs. The report focuses on CLARITIN and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- District Court patent litigation
- European supplementary protection certificates (SPCs)
- Clinical trials
- Annual sales revenues
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Topics Covered
- Profile for CLARITIN
- US Patents
- Expired US Patents
- US District Court Litigation
- International (ex US) Patents
- Supplementary Protection Certificates
- Clinical Trials
- Annual Sales Revenues
- Finished Product Suppliers
- Bulk API Sources
Companies Featured
-
Bayer Healthcare
- Lil' Drug Store Products
- Sigma-Aldrich
- Molport
- Abi Chem
- Vitas-M Laboratory
- Forechem
- Chemmol
- Abblis Chemicals
- Biochempartner
- Medchemexpress Mce
- Abachemscene
- Mcule
- Synblock Inc
- Act Chemical
- An Pharmatech
- Syntree
- Founder Pharma
- Labseeker
- Avachem Scientific
- Bide Pharmatech Ltd.
- Tocris Bioscience
- Biosynth
- Oxchem Corporation
- Clearsynth
- Phion Ltd
- Enovation Chemicals
- Abovchem Llc
- LGC Standards
- Activate Scientific
- Ochem
- King Scientific
- 001Chemical
- Ambeed
-
and many more...
For more information about this report visit https://www.researchandmarkets.com/research/wn2vml/claritin_drug?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190114005404/en/
Editor Details
-
Company:
- Business Wire
- Website: